2 consecutive boards for Jiuan Medical: Large-scale asset allocation business beginning to receive market attention; investment income and fair value changes subject to uncertainty

MaticHoleFiller · 2026-03-25T03:04:16+00:00

Jiuan Medical has attracted market attention due to its large-scale asset allocation business, with its stock price experiencing significant fluctuations recently. The company emphasizes that investment income and fair value are subject to multiple factors and face market and credit risks. Meanwhile, the sales of its test kit products are dependent on the U.S. market and face risks from demand volatility and trade policy changes.

MaticHoleFiller

2026-03-25 03:04:16

Abstract generation in progress

Reposted from: Cailian Press

【Jiuzhou Medical: Major Asset Allocation Business Begins to Attract Market Attention; Investment Returns and Fair Value Changes Are Uncertain】Cailian Press, March 19 — Jiuzhou Medical (002432.SZ) announced that its stock prices on March 18 and 19 showed a cumulative deviation of over 20% in closing prices over two consecutive trading days, indicating abnormal stock trading fluctuations. The company’s major asset allocation business has started to attract market attention. The company has always been committed to preserving and increasing asset value and continuously improving risk resistance. However, during the investment process, various factors such as domestic and international macroeconomic conditions, industry cycles, exchange rates, and interest rate fluctuations may introduce certain market and credit risks. Investment returns and fair value changes are also uncertain. Additionally, the redemption, sale, and realization of investment gains of investment targets are affected by the prices of related products and must comply with relevant trading settlement rules and agreements. There may be some liquidity risk compared to cash funds. The company’s past growth was mainly driven by a significant increase in sales of iHealth reagent kits, especially due to demand from U.S. government orders. The sales of the company’s home-use antigen self-test kits are directly related to demand in the U.S. market and are also influenced by local policies and market competition. Changes in these factors could reduce market demand for the kits and pose risks of performance fluctuations. Furthermore, the company has closely monitored U.S. tariff policy developments and adjusted strategies accordingly. However, if U.S. tariffs become more stringent in the future, the company’s operating performance could face risks from trade frictions and adjustments in the global supply chain.

Massive information, precise analysis, all on Sina Finance APP

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.